These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 29848078)

  • 1. Influence of ethanol on the metabolism of alprazolam.
    Huang Z; Xu Z; Wang H; Zhao ZQ; Rao Y
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):551-559. PubMed ID: 29848078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys.
    Ohtsuka T; Yoshikawa T; Kozakai K; Tsuneto Y; Uno Y; Utoh M; Yamazaki H; Kume T
    Drug Metab Dispos; 2010 Oct; 38(10):1806-13. PubMed ID: 20584745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered?
    Roedler R; Neuhauser MM; Penzak SR
    Ann Pharmacother; 2007 Apr; 41(4):653-8. PubMed ID: 17374625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.
    Midde NM; Gong Y; Cory TJ; Li J; Meibohm B; Li W; Kumar S
    Pharm Res; 2017 Sep; 34(9):1925-1933. PubMed ID: 28616684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of CYP3A by ethanol in multiple in vitro and in vivo models.
    Feierman DE; Melinkov Z; Nanji AA
    Alcohol Clin Exp Res; 2003 Jun; 27(6):981-8. PubMed ID: 12824820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
    Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
    Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alprazolam-ritonavir interaction: implications for product labeling.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
    Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic interaction between ethanol, high-dose alprazolam and its two main metabolites using human liver microsomes in vitro.
    Tanaka E; Nakamura T; Terada M; Shinozuka T; Honda K
    J Forensic Leg Med; 2007 Aug; 14(6):348-51. PubMed ID: 17631455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam.
    Drabant S; Tóth M; Bereczki A; Bajnógel J; Tömlö J; Klebovich I
    Eur J Clin Pharmacol; 2006 Jul; 62(7):587-8. PubMed ID: 16791582
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical pharmacokinetics of alprazolam. Therapeutic implications.
    Greenblatt DJ; Wright CE
    Clin Pharmacokinet; 1993 Jun; 24(6):453-71. PubMed ID: 8513649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and physiologic effects of alprazolam after a single oral dose in healthy mares.
    Wong DM; Davis JL; Alcott CJ; Hepworth-Warren KL; Galow-Kersh NL; Rice S; Coetzee JF
    J Vet Pharmacol Ther; 2015 Jun; 38(3):301-4. PubMed ID: 25427652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9.
    Wang R; Zhang H; Wang Y; Yu X; Yuan Y
    J Ethnopharmacol; 2016 Mar; 180():87-96. PubMed ID: 26806573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of In Vitro and Predictive In Silico Models to Study the Inhibition of Cytochrome P4503A by Stilbenes.
    Basheer L; Schultz K; Fichman M; Kerem Z
    PLoS One; 2015; 10(10):e0141061. PubMed ID: 26485399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of shikonin on the metabolism of lapatinib in vitro, and in vivo.
    Hu Y; Xie S; Xia H; Chen J; Yang Y; Zhan R
    Toxicol Appl Pharmacol; 2024 Jan; 482():116797. PubMed ID: 38160892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of CYP3A4 genetic polymorphism on crizotinib metabolism and drug-drug interactions.
    Wang J; Xu XY; Li XY; Luo JC; Zhang ZY; Chen J; Cai JP; Zhang LK; Qian JC
    Toxicol Appl Pharmacol; 2024 Aug; 489():117016. PubMed ID: 38925514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations.
    Niu L; Ding L; Lu C; Zuo F; Yao K; Xu S; Li W; Yang D; Xu X
    J Ethnopharmacol; 2016 Sep; 191():350-359. PubMed ID: 27318274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of alosetron on the pharmacokinetics of alprazolam.
    D'Souza DL; Levasseur LM; Nezamis J; Robbins DK; Simms L; Koch KM
    J Clin Pharmacol; 2001 Apr; 41(4):452-4. PubMed ID: 11304902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Investigation of Ligand Binding to the Peripheral Site in CYP3A4: Conformational Dynamics and Inhibitor Discovery.
    Du H; Li J; Cai Y; Zhang H; Liu G; Tang Y; Li W
    J Chem Inf Model; 2017 Mar; 57(3):616-626. PubMed ID: 28221037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of venlafaxine on the pharmacokinetics of alprazolam.
    Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
    Psychopharmacol Bull; 1998; 34(2):211-9. PubMed ID: 9641003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation.
    Molanaei H; Stenvinkel P; Qureshi AR; Carrero JJ; Heimbürger O; Lindholm B; Diczfalusy U; Odar-Cederlöf I; Bertilsson L
    Eur J Clin Pharmacol; 2012 May; 68(5):571-7. PubMed ID: 22159869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.